Jiyya ga mataki na ƙananan mataki IV Melanoma ya ba da bege
Interleukin-2 na melanoma na ƙwayar cuta yana daya daga cikin hanyoyin da za a bi don maganin cutar. Melanoma wanda ya yada fiye da fata zuwa gabobi masu nisa an kira "metastatic" (ko mataki na IV ) melanoma. Kodayake zaɓuɓɓukan kulawa a halin yanzu suna da iyakancewa, wasu mutane sun tsira wannan mummunan mataki na cutar. Akwai bincike mai zurfi a cikin wannan yanki amma har yanzu, an samu hanyoyin magance biyu kawai: interferon-alfa2b da kuma tsarin da ke kula da kwayoyin cuta mai lamba interleukin-2 (IL-2).
Idan masanin ilimin likitancinku ya bada shawarar IL-2, wannan zabin zai sa ku da muhimmancin bayanin da kuke buƙatar fahimtar yadda yake aiki, da tasirinta da kuma tasirinsa.
Interleukin-2
Har ila yau, an kira Proleukin da aldesleukin, Cibiyar Abinci da Drug ta hanyar IL-2 ta amince da ita don kula da melanoma a 1998. (Abin baƙin ciki, ba a yarda da wasu magunoma ba.)
IL-2 ya bambanta da miyagun ƙwayoyi na chemotherapy - shi ne ainihin ɓangaren jikin jikin ku. Yana da nau'in kwayoyin manzo da ake kira "cytokine" wanda aka ɓoye daga wasu kwayoyin don faɗakar da sauran kwayoyin game da mahaukaciyar cuta. Akalla iri-iri iri-iri na interleukins an gano tun daga shekarun 1970: IL-2 an san shi don karfafawa girma da maturation nau'i nau'in jini guda biyu, wanda ake kira "T da B lymphocytes." IL-2 da ake amfani dasu gameda melanoma ba ya fito ne daga jiki ba amma an samar da taro, ta hanyar amfani da fasahar aikin injiniya.
Ya na da kaya iri iri a matsayin nau'in halitta, amma yana da suna daban-daban, aldesleukin.
Tabbatar da amincin Interleukin-2
A cikin binciken da ya kai ga yarda, kashi 6 cikin 100 na marasa lafiya da aka zaɓa (wadanda ke cikin jiki da tunanin mutum) tare da metastatic melanoma yana da cikakkiyar amsa ga IL-2 mai girma, kuma kashi 10 cikin dari na da amsa.
Ana bada cikakkiyar amsawa a matsayin tsawon shekaru 10 (shekaru 10+ da ƙidayawa) kawar da cutar, ko da yake ba fasaha ba ne "magani". Ko da kuwa kalmar terminology, ita ce kawai magani da ke samuwa wanda har ma da yiwuwar irin wannan babban tabbaci da kuma tsayi sakamako. An lura da maganganu a marasa lafiya tare da wasu matakan metastases, ciki har da cikin huhu, hanta, ƙananan lymph, kayan laushi, glanders da kuma subcutaneous (zurfi) launi na fata. IL-2, duk da haka, ba a bayar da shawarar ga marasa lafiya tare da ƙwayar ƙwayar ƙwayar cuta ba.
An gudanar da gwajin gwaje-gwaje masu yawa (kuma ana gudanar da su) a cikin ƙoƙari na ƙara yawan karuwar amsawar IL-2 ta haɗuwa da wasu magunguna. Alal misali, binciken ya nuna yawan halayen da aka mayar dashi lokacin da aka ba IL-2 a hade tare da maganin alurar (kashi 22) idan aka kwatanta da IL-2 kadai (kashi 13). Abin takaici, da yawa ƙoƙari na hada IL-2 tare da kwayoyi masu amfani da ilimin chemotherapy (cisplatin, vinblastine, dacarbazine da sauransu) - wani tsarin da ake kira "biochemotherapy" - da sauran kwayoyi ( interferon-alfa2b , da dai sauransu), sun nuna babu wani cigaba mai mahimmanci a cikin kididdiga wanda yake da muhimmanci: lokacin rayuwa.
Amfani da Interleukin-2
IL-2 ana ba da jita-jita na jimla 15-minti a kowane sa'a 8 na kwanaki 5.
Kowace tsarin kulawa yana kunshe da tsawon hawan kwana 5 na rabuwa da rabuwa ta kwana 9 na hutawa, kuma darussa masu yawa sune al'ada. Za a iya kwatanta ku kusan wata guda bayan kammala aikinku na farko. Idan kuna amsawa, za a iya bayar da ku na biyu na magani don makonni 6 zuwa 12 bayan kammala karatun farko. Don samun cancanta don maganin IL-2, dole ne ku kasance cikin yanayin jiki mai kyau, tare da zuciya mai kyau, huhu, hanta, da kuma koda.
Hanyoyin Kayan Yanayi
IL-2 yana da sau da yawa, sau da yawa mai tsanani kuma wasu lokuta mawuyacin sakamako. Ya kamata a ba shi a asibitin karkashin kulawar likitan likita da aka samu a cikin amfani da wakilan anticancer.
Dole ne mai kulawa da kulawa mai kulawa da kwararrun likitoci a cikin likitancin zuciya ko magungunan kulawa mai tsanani. Rahoton mutuwar kwayoyi a cikin gwaji na marasa lafiya wadanda suka karbi IL-2 shine 2%.
Yawancin cututtuka masu illa sune saboda "lakabi," wanda ya fara nan da nan bayan an fara fara magani. Matsayi na Capillary sakamakon sacewar sunadarai daga jini wanda zai haifar da karuwar karfin jini. Sakamakon sakamako mafi rinjaye shine kamar haka:
- tashin zuciya, ciwo, zawo, asarar ci
- rauni da gajiya
- cututtuka-kamar bayyanar cututtuka (zazzabi, ciwon zuciya, ciwon kai da tsoka)
- low jini
- ciwo mai tsanani, zafi ciwo (angina)
- matsalolin numfashi saboda ruwa a cikin huhu
- riba mai nauyi, riƙewar ruwa
- shafi tunanin mutum (paranoia, hallucinations, rashin barci)
- itching, peeling fata
- anemia (ƙananan jinin jini)
- lowlet count count (kara da hadarin zub da jini)
- ƙananan jinin jini
- lalacewar koda
- bakin bakin
Wadannan cututtuka sun fi raguwa amma an ruwaito su a wasu mutane suna shan IL-2:
- mahaukaciyar zuciya, rukuni na zuciya
- numfashi na numfashi
- manyan cututtuka
- zubar da jini gastrointestinal
- matsalolin thyroid
- hanta matsaloli
- matsananciyar damuwa, rashi
Amfani / Abun hulɗar
IL-2 na iya haifar da cututtukan cututtukan kwayoyi da cututtuka mafi muni, don haka gaya wa likita idan kana da:
- matsalolin koda
- cututtukan zuciya
- ciwon hanta
- cutar huhu
- cuta mai riki
- ciwon maganin ka
- cututtuka
- wani allergies
- duk wani cuta mai ciwo
Har ila yau, sanar da likita game da duk wani magungunan da aka yi amfani da shi, ko magungunan magani da kuke amfani da su, musamman corticosteroids, indomethacin, maganin jini, antidepressants, magunguna masu rikitarwa ko wasu magungunan anticancer. Kada ka fara ko dakatar da wani magani ba tare da amincewar likita ba.
Lura: Wannan bayanin bazai iya rufe dukkan kariya, hulɗa ko tasiri mara kyau ba saboda wannan magani. Idan kana da wasu tambayoyi game da kowace miyagun ƙwayoyi kake ɗauka, tabbatar da duba tare da masu sana'a na kiwon lafiya.
Sources:
"Melanoma." Ƙungiyar Cibiyar Cutar Cancer ta kasa. V.1.2009. 27 Janairu 2009.
"Bayaniyar Bayanan Bayani." Novartis Pharmaceuticals Corp. 27 Janairu 2009.
Smith FO, Downey SG, Klapper JA, et al. Yin jiyya na melanoma ta hanyar amfani da interleukin-2 kadai ko tare da maganin alurar riga kafi. Cutar Cancer Res 2008 14: 5610-5618. 27 Janairu 2009.